Open Medicine (May 2024)

Cost-effectiveness of ambroxol in the treatment of Gaucher disease type 2

  • Milosavljević Miloš N.,
  • Gutić Medo,
  • Janjić Vladimir,
  • Veselinović Slađana,
  • Djordjić Milan,
  • Ivanović Radenko,
  • Milosavljević Jovana,
  • Janković Slobodan M.

DOI
https://doi.org/10.1515/med-2024-0970
Journal volume & issue
Vol. 19, no. 1
pp. 441 – 518

Abstract

Read online

Our aim was to compare the costs and efficacy of ambroxol in combination with imiglucerase with the costs and efficacy of imiglucerase only in the treatment of Gaucher disease type 2 (GD2) in the socio-economic settings of the Republic of Serbia, an upper-middle-income European economy.

Keywords